Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats.
Diabetes mellitus is a condition of increased blood glucose level in the body. Antihyperlipidemic drugs like statins and fibrates are widely used for prophylactic treatment in dyslipideamia and atherosclerosis. Diabetic dislipidemia exists with increased triglycerides, low HDL and high LDL levels. Hence, with oral hypoglycemic drugs, the addition of a lipid-lowering drug is necessary for controlling dislipidemia. In such a situation, there may be chances of drug-drug interactions between antidiabetic and antihyperlipidemic drugs. The present study is planned to evaluate the safety of gliclazide (antidiabetic) in the presence of pravastatin and gemfibrozil (antihyperlpidemic) in rats. Studies in normal and alloxan-induced diabetic rats were conducted with oral doses of gliclazide and their combination with pravastatin and gemfibrozil, with an adequate washout period in between the treatments. Blood samples were collected in rats by retroorbital puncture at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h. All the blood samples were analyzed for glucose by GOD -POD. Gliclazide (½ TD) produced hypoglycemic activity in normal and diabetic rats, with peak activity at 2 and 8 h. Pravastatin (TD) + gemfibrozil (TD) combination treatment increased the hypoglycemic effect of gliclazide in normal rats or diabetic rats when administered together. The interaction observed due to inhibition of both the enzymes (CYP 450 2C9 and CYP 450 3A4) responsible for the metabolism of gliclazide showed increased half-life, which was seen in the present study. Because concomitant administration of gliclazide with provastatin and gemfibrozil in diabetes is associated with atherosclerosis, it should be contraindicated or used with caution.
Pharmacology Division, Government College of Pharmacy, Bangalore - 560 027, India.
Cm
C
Sultanpur
S
S
Satyanarayana
Ns
N
Reddy
Ke
K
Kumar
S
S
Kumar
Clin Pharmacokinet. 1979 Sep-Oct;4(5):368-79
389528
Eur J Pharmacol. 1977 Jul 15;44(2):191-3
885168
J Clin Pathol. 1969 Mar;22(2):158-61
5776547
J Pharmacobiodyn. 1981 Jun;4(6):436-42
7288560
Drug Saf. 2000 Apr;22(4):313-20
10789825
Diabetes Res Clin Pract. 1993 May;20(2):147-54
8375268
Diabetes. 1998 Sep;47(9):1412-8
9726229
Diabetes Res Clin Pract. 1991;14 Suppl 2:S21-36
1794262
Clin Pharmacokinet. 1987 Jun;12(6):379-401
3301149
Diabetes Res Clin Pract. 1991;14 Suppl 2:S61-4
1794267
Eur J Clin Pharmacol. 1996;50(3):209-15
8737761
Int J Clin Pharmacol Res. 1986;6(6):441-9
3468088
Clin Pharmacokinet. 2000 Dec;39(6):397-412
11192473
J Diabetes Complications. 1994 Oct-Dec;8(4):235-9
7833500
Proc Soc Exp Biol Med. 1960 Aug-Sep;104:751-4
13741689
Drug Metab Dispos. 2001 Nov;29(11):1359-61
11602509
Science. 1995 Apr 21;268(5209):372-3
7716539